Table 3.

Frequency of antibodies against single FSPs and FSP combinations.

peptide	patients	healthy mutation carriers	healthy controls
AIM2(-1)	5.8% (4/69)	0.0% (0/31)	3.8% (2/52)
CASP5(-1)	4.3% (3/69)	6.5% (2/31)	1.9% (1/52)
ZNF294(-1)	4.3% (3/69)	0.0% (0/31)	0.0% (0/52)
MARCKS(-1)	2.9% (2/69)	0.0% (0/31)	1.9% (1/52)
TGFBR(-1)	10.1% (7/69)	9.7% (3/31)	5.8% (3/52)
TGFBR(-1)-N	11.6% (8/69)	0.0% (0/31)	5.8% (3/52)
TGFBR(-1)-C	7.2% (5/69)	19.4% (6/31)	3.8% (2/52)
TAF1B(-1)	11.6% (8/69)	6.5% (2/31)	1.9% (1/52)
all tested FSPs	29.0% (20/69)	29.0% (9/31)	15.4% (8/52)